Update on Lupuzor™ Pivotal Phase III Study

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide an update of its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. Study summary as at 1st November 2017 • 200 patients successfully recruited and randomised (dosed) – all patients in the study have now passed the 9 months stage – 116 of patients (58%) have completed the full 12 months of the study Continued robust safety record which remains consistent with Lupuzor™’s product profile as shown in its previous Phase IIb study Top line results remain on track to be reported in Q1 2018 Commenting on the trial update, Tim McCarthy, Chairman of ImmuPharma said: “The trial continues to progress on track and on time, with all patients in the study now having passed the 9 month stage and 116 patients (58%) having completed the full 12 months. “Most importantly, we continue to see robust safety within the study which is as equally important as the efficacy profile, in order for Lupuzor™ to be proactively prescribed by specialists to Lupus patients, who urgently require a more effective treatment for their condition. “We look forward with confidence to reporting top line results of the study in Q1 2018.” For more information on the trial please visit: https://clinicaltrials.gov/ct2/show/NCT02504645 This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

The release as fetched from its publisher. immupharma.co.uk ↗